Home » Stocks » ADMA Biologics

ADMA Biologics Inc. (ADMA)

Stock Price: $3.03 USD 0.12 (4.12%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
Pre-market: $3.04 +0.01 (0.33%) Aug 14, 7:00 AM

Stock Price Chart

Key Info

Market Cap 261.64M
Revenue (ttm) 37.25M
Net Income (ttm) -61.42M
Shares Out 86.35M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $3.03
Previous Close $2.91
Change ($) 0.12
Change (%) 4.12%
Day's Open 2.90
Day's Range 2.84 - 3.04
Day's Volume 3,192,584
52-Week Range 1.45 - 5.48

More Stats

Market Cap 261.64M
Enterprise Value 282.64M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 86.35M
Float 67.93M
EPS (basic) -0.85
EPS (diluted) -0.88
FCF / Share -1.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.56M
Short Ratio 1.86
Short % of Float 15.62%
Beta 2.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.02
PB Ratio 3.21
Revenue 37.25M
Operating Income -50.77M
Net Income -61.42M
Free Cash Flow -99.02M
Net Cash -21.00M
Net Cash / Share -0.24
Gross Margin -27.26%
Operating Margin -136.31%
Profit Margin -164.90%
FCF Margin -265.85%
ROA -18.96%
ROE -99.24%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(225.41% upside)
Current: $3.03
Target: 9.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth72.79%-25.37%113.49%48.53%21.34%92.84%174.35%46.92%-
Gross Profit-10.16-25.21-6.404.302.872.171.040.450.55
Operating Income-41.42-60.29-39.31-17.33-15.51-16.02-15.04-7.91-4.62
Net Income-48.28-65.74-43.76-19.52-17.97-16.81-15.53-7.30-5.90
Shares Outstanding54.3545.1922.9012.1510.419.296.535.270.35
Earnings Per Share-0.89-1.45-1.91-1.61-1.73-1.81-2.38-1.39-16.72
Operating Cash Flow-76.19-62.68-37.27-18.27-15.42-14.70-10.89-6.90-1.43
Capital Expenditures-3.81-2.10-2.68-0.07-0.03-2.32-0.20-0.12-
Free Cash Flow-80.01-64.77-39.95-18.34-15.44-17.03-11.08-7.02-1.43
Cash & Equivalents26.7526.7548.6115.3116.8421.8829.1013.000.44
Total Debt83.4344.1042.9720.2215.6914.775.083.970.55
Net Cash / Debt-56.68-17.355.64-4.921.147.1124.029.03-0.11
Book Value26.1919.7740.33-4.460.826.0121.579.420.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ADMA Biologics Inc.
Country United States
Employees 313
CEO Adam S. Grossman

Stock Information

Ticker Symbol ADMA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADMA


ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.